Alimera Sciences, Inc. (ALIM)
-NasdaqGM 4.44 
0.01(0.23%) May 24, 3:59PM EDT
| Prev Close: | 4.43 |
|---|
| Open: | 4.42 |
|---|
| Bid: | 3.56 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.58 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.40 - 4.48 |
|---|
| 52wk Range: | 1.26 - 5.10 |
|---|
| Volume: | 35,367 |
|---|
| Avg Vol (3m): | 64,363 |
|---|
| Market Cap: | 140.06M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.93 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ALIMERA SCIENCES INC FinancialsEDGAR Online Financials(Fri, May 17)
- Ophthalmology Innovators: Will InSite Follow Recent Successes?at Seeking Alpha(Thu, May 16)
- Monday Sector Leaders: Biotechnology, Drugsat Forbes(Mon, May 13)
- Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013at Seeking Alpha(Mon, May 13)
- ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Alimera Sciences Reports First Quarter 2013 Financial ResultsPR Newswire(Thu, May 9)
- ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhiEDGAR Online(Thu, May 9)
- Q1 2013 Alimera Sciences Inc Earnings Release - After Market CloseCCBN(Thu, May 9)
- Alimera Sciences Secures $20 Million Debt FacilityPR Newswire(Wed, May 8)
- ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitEDGAR Online(Wed, May 8)
- Alimera Sciences announces first patient treated with Iluvientheflyonthewall.com(Tue, May 7)
- Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®PR Newswire(Tue, May 7)
- ALIMERA SCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial ResultsPR Newswire(Fri, May 3)
- Alimera Sciences Announces New PDUFA Date For ILUVIEN®PR Newswire(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.85 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.24 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals.
View More